Literature DB >> 27335522

Risperidone Induced Benign Intracranial Hypertension Leading to Visual Loss.

Sushil Thomas Alexander1, Dheeraj Kattula2, Pavithra Mannam3, Ramya Iyyadurai1.   

Abstract

Benign intracranial hypertension (BIH) is a rare but potentially serious condition causing visual loss. Occasionally, medication use has been associated with the occurrence of BIH. We report the case of a 40-year-old obese lady being treated with risperidone for schizophrenia who presented with features of BIH. We report this case, occurring for the 1(st) time in India, to emphasize that a commonly used atypical antipsychotic drug can rarely cause BIH leading to visual loss.

Entities:  

Keywords:  Intracranial hypertension; medication; risperidone; visual loss; weight gain

Year:  2016        PMID: 27335522      PMCID: PMC4904763          DOI: 10.4103/0253-7176.183075

Source DB:  PubMed          Journal:  Indian J Psychol Med        ISSN: 0253-7176


INTRODUCTION

Benign intracranial hypertension (BIH) is a well-known entity where elevated intracranial cerebrospinal fluid (CSF) pressures exist in the absence of obvious infections, venous thrombosis or intracranial mass lesions.[1] BIH has been synonymously described as pseudotumor cerebri or idiopathic intracranial hypertension. Many drugs have been associated with the occurrence of BIH. We report a lady, being treated with risperidone for schizophrenia, who presented with symptoms of BIH. To the best of our knowledge, only four such risperidone-induced cases have been reported in world literature with none from India.[2345] We report this case for its rare but serious morbidity occurring with a common antipsychotic medication.

CASE REPORT

A 40-year-old obese lady presented with a severe holocranial headache for 10 days. She had associated nausea, vomiting, and rapid onset of painless loss of vision in both the eyes which progressed over 2 days. She was a known case of schizophrenia on treatment under psychiatry for the past 10 years. She was treated with olanzapine and later with fluphenazine decanoate when she was irregular with medications. This was subsequently changed to risperidone after symptomatic improvement. She was only on 4 mg of risperidone for the past 1-year. She has had associated history of weight gain over the last 4 years which had rapidly worsened after starting risperidone. She did not have any other comorbidity. On examination, she was obese with a body mass index of 32.4 kg/m2. Her general and systemic examinations were normal. On ophthalmological evaluation, the pupils were equal but nonreactive bilaterally. There was the perception of light in the right eye and none at all in the left. Bilateral papilledema with primary optic atrophy in the left eye was noticed on fundus examination. On testing eye movements, she had bilateral restriction of lateral gaze. She was unable to do formal visual field testing due to the poor vision. Differential diagnosis considered included meningitis, cortical venous thrombosis, demyelinating illness with optic neuritis, and idiopathic intracranial hypertension. Magnetic resonance imaging (MRI) of the brain revealed increased diameter of the optic nerve sheath with flattening of the posterior sclera margin with prominent perioptic halo [Figure 1]. There was also a partially empty sella [Figure 2] and narrowing of the junction of the transverse-sigmoid sinuses [Figure 3] which were all suggestive of intracranial hypertension. The subsequent CSF study was normal except for the elevated opening pressure of 35 cm of water. A magnetic resonance venogram was also done to rule out cortical venous thrombosis. Visual evoked potential testing showed absent waveform in the left optic nerve.
Figure 1

T2-weighted magnetic resonance imaging image of brain showing tortuosity of optic nerves with prominent perioptic fluid halo and flattened posterior scleral margin

Figure 2

T1-weighted sagittal image magnetic resonance imaging brain showing empty sella

Figure 3

Magnetic resonance venography brain image (postcontrast dynamic) showing narrowing of transverse-sigmoid junction with no thrombosis or abnormal collaterals

T2-weighted magnetic resonance imaging image of brain showing tortuosity of optic nerves with prominent perioptic fluid halo and flattened posterior scleral margin T1-weighted sagittal image magnetic resonance imaging brain showing empty sella Magnetic resonance venography brain image (postcontrast dynamic) showing narrowing of transverse-sigmoid junction with no thrombosis or abnormal collaterals A diagnosis of BIH was made based on the modified Dandy's diagnostic criteria. She was then initiated on acetazolamide and mannitol for medical management of BIH. In view of the persistent headache, papilledema, and visual loss a surgical option was considered. As she had developed features of left optic atrophy, it was decided that a thecoperitoneal shunt procedure would be preferable to an optic nerve sheath fenestration. She thus underwent a lumbar thecoperitoneal shunt procedure. Postoperatively, her headache improved, and right eye vision improved from the perception of light positive to finger counting at six feet. Vision in the left eye remained negative for the perception of light. Risperidone was stopped from the onset of the present admission. Aripiprazole was started later by psychiatry as part of her maintenance treatment. On review, a month later, she was doing well with no headache or further loss of vision.

DISCUSSION

The term BIH is a misnomer as it is not entirely benign.[6] In adults, it is associated with raised CSF pressures above 25 cm of water. The modified Dandy's diagnostic criteria have been used in making a formal diagnosis of BIH.[7] This involves ruling out infective causes for raised intracranial hypertension with CSF testing. In addition, thrombotic reasons and intracranial mass lesions causing intracranial hypertension should be ruled out with MRI and magnetic resonance venogram. It usually occurs in females of 15-45 years of age.[1] Rapid weight gain and obesity have been previously implicated in the pathogenesis of this condition although the exact mechanisms are unclear.[8] The resulting central obesity increases intra-abdominal pressure, pleural pressure, cardiac filling pressure, and central venous pressure is proposed to increased intracranial venous pressure and cause BIH. Increased leptin in obesity may contribute to the elevated intracranial hypertension in obesity.[9] Furthermore, apneic episodes in these obese individuals may further predispose them to developing elevated intracranial hypertension. Many drugs such as tetracyclines, retinoids, growth hormone, oral contraceptive pills, nalidixic acid, steroid withdrawal, Vitamin A, lithium, fluroquinolole, and danazol have been implicated in causing BIH.[1] Till date, risperidone causing BIH has only been reported in 4 cases. A detailed drug history is thus very important as stopping the culprit drug is a modifiable risk factor for the treatment of BIH.[3] Benign intracranial hypertension must be diagnosed early as up to 25% of patients can go on to develop acute vision loss due to optic nerve atrophy.[10] Bedside fundus examination in the setting of persistent headache is a simple method of rapidly detecting papilledema and thus preventing subsequent visual morbidity. Benign intracranial hypertension is treated with medical measures to reduce intracranial pressures like acetazolamide, furosemide, and intravenous mannitol administration.[6] In case of worsening vision or persistent headache despite optimal medical management early. Shunt procedures must be considered in BIH to prevent irreversible optic nerve damage.[11] Currently, the best surgical option in BIH from among optic nerve sheath fenestration, CSF shunt procedures or venous shunting is still debatable.[12] Further sustaining the clinical benefit in BIH includes lifestyle modification with low salt, low-calorie diet, and regular exercise to reduce weight.[13] Bariatric surgery is an accepted alternative option to promote weight loss in BIH where medical measures have been unsuccessful.[14]

CONCLUSION

Rapid weight gain due to medication is associated with BIH. Drug-induced BIH is potentially modifiable and must be detected early to prevent permanent visual loss. We report this case for its rare presentation and to emphasize an uncommon side effect of a commonly used atypical antipsychotic.
  13 in total

Review 1.  Diagnostic criteria for idiopathic intracranial hypertension.

Authors:  Deborah I Friedman; Daniel M Jacobson
Journal:  Neurology       Date:  2002-11-26       Impact factor: 9.910

2.  Lumboperitoneal shunt for idiopathic intracranial hypertension: patients' selection and outcome.

Authors:  Waleed F El-Saadany; Ahmed Farhoud; Ihab Zidan
Journal:  Neurosurg Rev       Date:  2011-09-29       Impact factor: 3.042

3.  [Pseudotumor cerebri as side effect of treatment with risperidone].

Authors:  R Velázquez-Fragua; M C Roche-Herrero; S Noval-Martín; G Muñoz-García; F Rubio-Rodríguez; A Martínez-Bermejo
Journal:  Rev Neurol       Date:  2008 Jun 16-30       Impact factor: 0.870

4.  [Idiopathic intracranial hypertension and obesity].

Authors:  M Tirza Naarden; Alie Schuitemaker; Hilde M H Braakman; Tristan P C van Doormaal; Giorgio L Porro; J S Rob Straver
Journal:  Ned Tijdschr Geneeskd       Date:  2015

5.  Risperidone induced weight gain leading to benign intracranial hypertension.

Authors:  Hira Ahmed; Hala Ali
Journal:  BMJ Case Rep       Date:  2011-07-27

Review 6.  An update on idiopathic intracranial hypertension.

Authors:  Matthew J Thurtell; Beau B Bruce; Nancy J Newman; Valérie Biousse
Journal:  Rev Neurol Dis       Date:  2010 Spring-Summer

7.  Serum leptin level in women with idiopathic intracranial hypertension.

Authors:  Y Lampl; Y Eshel; A Kessler; A Fux; R Gilad; M Boaz; Z Matas; M Sadeh
Journal:  J Neurol Neurosurg Psychiatry       Date:  2002-05       Impact factor: 10.154

8.  Low energy diet and intracranial pressure in women with idiopathic intracranial hypertension: prospective cohort study.

Authors:  Alexandra J Sinclair; Michael A Burdon; Peter G Nightingale; Alexandra K Ball; Peter Good; Timothy D Matthews; Andrew Jacks; Mark Lawden; Carl E Clarke; Paul M Stewart; Elizabeth A Walker; Jeremy W Tomlinson; Saaeha Rauz
Journal:  BMJ       Date:  2010-07-07

Review 9.  Surgical and endovascular interventions in idiopathic intracranial hypertension.

Authors:  Arielle Spitze; Amina Malik; Andrew G Lee
Journal:  Curr Opin Neurol       Date:  2014-02       Impact factor: 5.710

Review 10.  Bariatric surgery for the treatment of idiopathic intracranial hypertension.

Authors:  Jared Fridley; Rod Foroozan; Vadim Sherman; Mary L Brandt; Daniel Yoshor
Journal:  J Neurosurg       Date:  2010-01-22       Impact factor: 5.115

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.